STO · HEART.ST
Scandinavian Real Heart AB (Publ)
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
Loading market information…
STO · SCIB.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:20 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SciBase Holding AB (publ)’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SciBase Holding AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -SEK 6.67+20.0% vs estimate |
| SEK 8.60M+10.23% vs estimate |
| Q3 2024 | Nov 12, 2024 | -SEK 0.080.0% vs estimate | SEK 8.41M+5.76% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 1.25SEK 0.00 (0.0%)
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 31.69% below the high.
SEK 8.00+SEK 0.12 (+1.52%)
Arcoma AB’s quoted price sits in the lower half of its reported 52-week range, 20.4% below the high.
SEK 0.37+SEK 0.05 (+15.94%)
Biovica International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
SEK 3.67SEK 0.00 (0.0%)
Scandinavian ChemoTech AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 52.71% below the high.
SEK 0.17+SEK 0.00 (+1.49%)
Nanologica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 92.44% below the high.
SEK 7.61+SEK 0.01 (+0.13%)
Vivesto AB’s quoted price sits in the lower half of its reported 52-week range, 72.12% below the high.
SEK 0.04-SEK 0.03 (-36.78%)
Immunovia AB’s quoted price sits in the lower half of its reported 52-week range, 87.62% below the high.
